Synergy Medical Laboratories INC

Synergy Medical Laboratories INC was paid $2.42M by Medicaid between Jan 2018 and Dec 2024, across 119 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 23% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#51 of 122

Median peer was paid$1.29M

This provider vs. median1.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,435	$96K
2019	3,495	$76K
2020	3,799	$61K
2021	9,865	$19K
2022	6,509	$54K
2023	63,054	$805K
2024incomplete	83,408	$1.31M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	23%	7,195	6,247	$564K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	23%	24,124	18,105	$556K
86480		4.6%	2,436	2,290	$111K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	4.2%	8,135	7,091	$102K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	3.3%	4,070	3,743	$79K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.9%	2,244	2,126	$70K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.9%	2,243	2,126	$70K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.6%	2,770	1,897	$63K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.1%	5,073	3,844	$50K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.9%	2,790	2,610	$47K
80061	Lipid panel	1.7%	4,833	4,472	$41K
86803		1.6%	2,872	2,675	$38K

107 more codes

U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.5%	726	$37K
86704		1.3%	2,845	$31K
80053	Comprehensive metabolic panel	1.2%	4,599	$28K
87350		1.2%	2,570	$28K
86706		1.1%	2,734	$26K
87340		<1%	2,874	$24K
83036	Hemoglobin; glycosylated (A1C)	<1%	4,191	$20K
80361		<1%	1,808	$19K
80356		<1%	1,800	$19K
80050	General health panel	<1%	867	$17K
80373		<1%	1,813	$15K
80372		<1%	1,813	$15K
80365		<1%	1,818	$15K
80364		<1%	1,814	$15K
80358		<1%	1,814	$14K
80354		<1%	1,814	$14K
82248		<1%	4,675	$14K
80323		<1%	1,772	$14K
80370		<1%	1,791	$13K
81235		<1%	85	$13K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,910	$13K
80348		<1%	1,814	$11K
80368		<1%	1,782	$11K
80366		<1%	1,807	$11K
80353		<1%	1,805	$11K
80359		<1%	1,807	$10K
80360		<1%	1,799	$10K
80349		<1%	1,807	$10K
80355		<1%	1,808	$10K
83992		<1%	1,803	$9K
87522	Neg quan hep c or qual rna	<1%	397	$9K
80346		<1%	1,805	$9K
86709		<1%	1,770	$8K
80345		<1%	1,796	$8K
80336		<1%	1,951	$8K
80333		<1%	1,753	$8K
80338		<1%	1,751	$8K
86708		<1%	804	$8K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	604	$7K
80325		<1%	1,808	$7K
82140		<1%	791	$4K
84443	Thyroid stimulating hormone (TSH)	<1%	1,145	$4K
86592		<1%	2,637	$3K
82607		<1%	773	$3K
82107		<1%	61	$3K
80321		<1%	1,049	$3K
82728		<1%	722	$3K
84439		<1%	937	$2K
87181		<1%	67	$2K
82746		<1%	596	$2K
86696		<1%	156	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	443	$2K
84153		<1%	278	$2K
81001		<1%	1,447	$1K
83615		<1%	897	$1K
82977		<1%	877	$1K
84481		<1%	368	$1K
86695		<1%	157	$1K
84403		<1%	79	$862.52
81003		<1%	1,273	$861.42
84550		<1%	836	$824.41
84270		<1%	291	$761.22
84436		<1%	509	$676.06
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	14	$667.29
83721		<1%	277	$643.38
36415	Collection of venous blood by venipuncture	<1%	2,825	$627.35
87076		<1%	88	$453.05
84146		<1%	274	$442.80
86141		<1%	155	$441.85
82043		<1%	340	$427.52
84144		<1%	258	$409.40
82570		<1%	390	$363.42
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	17	$350.00
82627		<1%	235	$337.38
85027		<1%	258	$292.08
83735		<1%	369	$271.37
85610		<1%	92	$264.53
82105		<1%	16	$214.72
85652		<1%	479	$199.65
82270		<1%	159	$175.92
83090		<1%	209	$166.29
84100		<1%	138	$157.00
83540		<1%	209	$138.71
83550		<1%	167	$111.55
83690		<1%	98	$108.57
82150		<1%	246	$98.79
80047		<1%	62	$94.80
83525		<1%	61	$82.08
84479		<1%	230	$72.67
80362		<1%	1,761	$31.78
84480		<1%	206	$21.65
84703		<1%	12	$6.00
81232		0%	14	$0.00
86328		0%	49	$0.00
81381		0%	14	$0.00
81408		0%	14	$0.00
84402		0%	169	$0.00
82550		0%	154	$0.00
83001		0%	103	$0.00
82670		0%	103	$0.00
86317		0%	152	$0.00
82164		0%	14	$0.00
83002		0%	103	$0.00
81400		0%	14	$0.00
81225		0%	13	$0.00
86593		0%	12	$0.00
81350		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGURNANI, ARVIND (LAB MANAGER)

Same official

Other billing entities under GURNANI, ARVIND

Full network →

Provider	Location	Paid
Capital Health Laboratory LLC	Keyport, NJ	$683K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.